Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis said it was targeting annual sales growth of 5% per year until 2027 and a core operating income margin of about 40% by 2027, driven by innovative drugs on the market, after it severed ownership ties to its generic-drugs business.

Novartis aims for 5% annual sales growth through 2027

Ad hoc announcement pursuant to Art. 53 LR  ‘Pure-play' innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth Mid-term sales guidance upgrade to 5% CAGR (2022-27), with core operating income margin of ~40%+ by 2027, driven by continued strong momentum of key growth drivers   Confidence to grow mid-single digit longer-term based on the foundational strength of de-risked existing brands and pipeline assets Focused strategy and financial discipline has delivered robust sales, core operating income and free cash flow growth Industry-leading performance across priority ESG ratings and remain committed to creating value through focusing on material ESG factors Basel, November 28, 2023 — Novartis executives are meeting investors and analysts today at an event in London, U.K., to showcase the company's ‘pure play' innovative medicines strategy and focused Research and Development pipeline.

Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day

Legend Biotech

Legend Biotech Corporation (NASDAQ:LEGN) highlighted an exclusive license agreement struck with Novartis AG (ADR) (NYSE:NVS) worth up to $1.11 billion as it released third-quarter results. Under the agreement, its Legend Biotech Ireland subsidiary has granted Novartis the rights to develop, manufacture and commercialize its CAR-T cell therapy candidate LB2102 and other potential chimeric antigen receptor T-cell therapies selectively targeting Delta-like ligand 3 (DLL3).

Legend Biotech highlights Novartis deal worth up to $1.11BN alongside 3Q results

Basel, November 20, 2023 — Novartis will present data from over 100 trials across its breast cancer and hematology portfolios at the 2023 San Antonio Breast Cancer Symposium (SABCS) and the American Society of Hematology (ASH) Annual Meeting & Exposition. The new data will highlight the latest advances across our breast cancer and hematology portfolios and pipeline, such as the Phase III NATALEE trial and Phase III APPLY-PNH trial.

Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH

Novartis AG (NYSE:NVS ) 10th Annual ESG Investor Event Conference November 13, 2023 10:30 AM ET Company Participants Maria Victoria Cuevas - IR Vas Narasimhan - CEO Lutz Hegemann - President, Global Health & Sustainability Thierry Diagana - Head, Global Health Research Sujata Vaidyanathan - Global Development Head Paul Penepent - Head Finance Reporting & Accounting Dr. Klaus Moosmayer - Chief Ethics, Risk & Compliance Officer Maria Victoria Cuevas Good morning and good afternoon. Thank you so much for joining our 10th Annual ESG Investor Event.

Novartis AG (NVS) 10th Annual ESG Investor Event Conference (Transcript)

Basel, November 9, 2023 — Novartis today announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib – a highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor – in people with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines1. In the studies, remibrutinib met all primary and secondary endpoints at Week 121. Remibrutinib demonstrated superiority in change from baseline vs placebo in weekly urticaria activity (UAS7), itch (ISS7) and hives (HSS7) at Week 121. Significantly more patients achieved well-controlled disease (UAS7≤6) with remibrutinib vs placebo, as early as Week 2 which was sustained at Week 12, and about one third of patients achieved complete absence of itch and hives at Week 121. Data are being presented at the 2023 American College of Allergy, Asthma and Immunology Scientific Meeting in Anaheim, California, November 9–13.

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2

AbbVie

Pfizer

AbbVie should be poised to return to rapid growth and recently boosted its dividend. Novartis' spin-off of Sandoz doesn't diminish its attractiveness for income investors.

3 Spectacular High-Yield Dividend Stocks to Buy in November

Basel, October 31, 2023 — Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial.

Novartis says drug candidate is successful in rare kidney disease trial

Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs.

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Novartis recently completed the spin-off of Sandoz, which improved its growth and margin profile. The biopharma business is in good shape, with a decent collection of high-growth products and pipeline opportunities. The recent share price correction and the spin-off of Sandoz put the company in a better position to deliver shareholder value in the following years.

New And Improved Novartis

Church & Dwight

Clorox

Fortis

Johnson & Johnson

Kimberly-Clark

Coca-Cola

McDonald's

MGE Energy

PepsiCo

Investors are worried about soaring interest rates, a pending government shutdown, wars around the world, and a recession looming next year. History is very clear, market timing is the WORST thing you can possibly try. None of the best investors in history do it, and neither should you. Dividend aristocrats and low-volatility blue chips are two proven ways to beat the market with lower volatility. Low-volatility aristocrats are the ultimate way to sleep well at night.

10 High-Yield Dividend Aristocrats Perfect For What's Coming Next

Novartis just spun off Sandoz, its generic division. The company has a huge pipeline of upcoming drug candidates.

2 Green Flags and 1 Red Flag for Novartis Stock

American Airlines

Clearfield

Delta Air Lines

Deutsche Bank

Raytheon Technologies

Take-Two Interactive Software

Despite multiple macroeconomic issues in the past year, the market looks to finally be turning back up as 2024 nears. In 2022 and 2023, unexpected downturns from the bear market, threats of an impending recession, and inflationary pressure brought down hundreds of growing companies.

7 Undervalued Stocks to Buy Before Everyone Else

Novartis AG (NYSE:NVS ) Q3 2023 Earnings Call Transcript October 24, 2023 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Andrew Baum - Citi Kerry Holford - Berenberg Emmanuel Papadakis - Deutsche Bank Florent Cespedes - Societe Generale Seamus Fernandez - Guggenheim Securities Simon Baker - Redburn Richard Vosser - JPMorgan Graham Parry - Bank of America Mark Purcell - Morgan Stanley Stephen Scala - TD Cowen Peter Welford - Jefferies Operator Good morning, and good afternoon, and welcome to the Novartis Q3 2023 Results Release Conference Call and Live Webcast. Please note that during the presentation, all participants will be in a listen-only mode, and the conference is being recorded.

Novartis AG (NVS) Q3 2023 Earnings Call Transcript

Novartis stock inched higher Tuesday after the firm hiked its earnings outlook for the third time this year following its Sandoz spinoff.

Novartis Hikes Its Earnings Outlook For The Third Time This Year

Novartis AG (NVS) Shareholder Analyst Call (Transcript)

Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income.

Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View

The Swiss pharmaceutical company says its transition to a pure-play innovative medicines business is now complete following the spinoff of Sandoz, its generic drugs unit.

Novartis Begins New Era With Profit Beat and Guidance Hike

Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun off and listed on Oct 4.

Novartis lifts 2023 earnings forecast for third time

Sandoz Group AG

Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing operations 2 Q 3 sales grew +12% (cc, +12% USD) with core operating income growing +21% (cc, +17% USD) Growth driven by continued strong performance from Kesimpta (+124% cc), Entresto (+31% cc), Kisqali (+76% cc), Pluvicto (+217% cc) and Scemblix (+157% cc) Q3 operating income grew +13% (cc, -4% USD) driven by higher sales and lower restructuring charges, partly offset by higher impairments through discontinuation of early stage development projects Q3 net income grew +37% (cc, +14% USD) mainly due to higher operating income Q3 free cash flow 3 was USD 5.0 billion (+24% USD) driven by higher net cash flows from operating activities Q3 core EPS grew +29% (cc, +24% USD) to USD 1.74 Strong nine months performance with sales growing +10% (cc, +8% USD) and core operating income growing +19% (cc, +13% USD) Q3 key innovation milestones, including positive Ph3 data for multiple pipeline assets with blockbuster potential: Cosentyx – FDA approval for intravenous formulation in three indications (PsA, AS, nr-axSpA)

Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance

Basel, October 23, 2023 — Novartis today presents data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium showed that Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with androgen receptor pathway inhibitor (ARPI) therapy, compared to a change in ARPI1.

Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting

Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.

Novartis (NVS) to Report Q3 Earnings: What's in the Offing?

Gilead Sciences

Haleon PLC

Medtronic

Merck

West Pharmaceutical Services

Zimmer Biomet Hlds

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

7 Healthcare Stocks to invest in for a Healthy Future

Basel, October 20, 2023 — Novartis will present late-breaking results from a prespecified exploratory subgroup analysis of invasive disease-free survival (iDFS) from the pivotal Phase III NATALEE trial at the European Society for Medical Oncology (ESMO) Congress 2023. After 27.7 months of follow-up, the iDFS benefit with Kisqali® (ribociclib) plus endocrine therapy (ET) was consistent across key prespecified subgroups, compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC) (see table below)1. Results were also consistent with those in the overall trial population, reinforcing that the benefit was not driven by a specific patient subgroup1 ,2.

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

News for Novartis Stock (NVS)